GO-MORE Study An open-label study assessing the addition of subcutaneous Golimumab to conventional disease-modfifying antirheumatic drug (DMARD) therapy in biologic-naive subjects with rheumatoid arthritis.

Research Project

 | 

01.11.2009

 - 31.10.2011